Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Phase I/II Study of KESONOTIDE™, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours

NCT06926075 is registered in ClinicalTrials.gov with Filamon LTD as lead sponsor.

NCT NCT06926075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06926075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Phase I/II Study of KESONOTIDE™, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours
Lead sponsor
Filamon LTD
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 7, 2025
Completion date
October 26, 2027
Enrollment
80 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, glioblastoma multiforme (gbm), lung cancers, ovarian cancer, pancreas cancer, prostate cancers, skin cancer